Theralase Technologies Inc.(TLTFF)
USD --+0.00%
Reward46Moderate
Risk54Moderate
📊75%Data
Revenue down 19% YoY
TLTFF
+0.0 · +0.00%
USD · OTCQB
Theralase Technologies Inc. | Healthcare
Earnings Deterioration
Market Cap:55.63M
ℹ️
Reward Rating
46
Moderate
Bottom 25% (model universe)
75% data coverage
ℹ️
Risk Rating
54
Moderate
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on TLTFF to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Theralase Technologies Inc.?

, a clinical stage pharmaceutical company, engages in the research, development, and commercialization of light activated photo dynamic compounds and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally.

TLTFF · Verdict

Moderate reward · elevated risk

TLTFF's standout is volatility; cash flow and profitability weigh on the picture.

Based on 88% data coverage

TLTFF · Verdict

What’s working & what to watch

Strengths 1

  • Volatility80/100

    Top decile vs peers

Watchouts 2

  • Cash flow16/100

    -324% free-cash-flow margin

  • Profitability31/100

    -412% net margin · -269% ROE

Model-based scoring. For information only — not financial advice.

What is Theralase Technologies Inc.?

, a clinical stage pharmaceutical company, engages in the research, development, and commercialization of light activated photo dynamic compounds and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. The company operates through Drug Division and Device Division segments. The company is listed on the OTCQB in USA, operating in the Healthcare sector, with a market capitalisation of 55.63M.

Financial Highlights

Investment Breakdown

📈 Growth
Growth trend is developing — watch for revenue consistency over upcoming quarters.
💰 Profitability
Thin or inconsistent margins weigh on earnings quality.
⚠️ Risk
Risk profile appears balanced versus broad market conditions.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (46)

The scoring profile indicates limited reward potential at this time, with valuation and momentum offering the most support. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap55.63M
P/E RatioN/A
Dividend YieldN/A
52 Week High0.26
52 Week Low0.1
Last AnnualDecember
IPO DateN/A
IncorporatedUSA
Shares Outstanding265M
No. of EmployeesN/A
IndustryMedical Devices
ExchangeOTCQB
Beta0.459
CurrencyUSD · Reports in CAD